Search anything and hit enter
  • Teams
  • Members
  • Projects
  • Events
  • Calls
  • Jobs
  • publications
  • Software
  • Tools
  • Network
  • Equipment

A little guide for advanced search:

  • Tip 1. You can use quotes "" to search for an exact expression.
    Example: "cell division"
  • Tip 2. You can use + symbol to restrict results containing all words.
    Example: +cell +stem
  • Tip 3. You can use + and - symbols to force inclusion or exclusion of specific words.
    Example: +cell -stem
e.g. searching for members in projects tagged cancer
Search for
Count
IN
OUT
Content 1
  • member
  • team
  • department
  • center
  • program_project
  • nrc
  • whocc
  • project
  • software
  • tool
  • patent
  • Administrative Staff
  • Assistant Professor
  • Associate Professor
  • Clinical Research Assistant
  • Clinical Research Nurse
  • Clinician Researcher
  • Department Manager
  • Dual-education Student
  • Full Professor
  • Honorary Professor
  • Lab assistant
  • Master Student
  • Non-permanent Researcher
  • Nursing Staff
  • Permanent Researcher
  • Pharmacist
  • PhD Student
  • Physician
  • Post-doc
  • Prize
  • Project Manager
  • Research Associate
  • Research Engineer
  • Retired scientist
  • Technician
  • Undergraduate Student
  • Veterinary
  • Visiting Scientist
  • Deputy Director of Center
  • Deputy Director of Department
  • Deputy Director of National Reference Center
  • Deputy Head of Facility
  • Director of Center
  • Director of Department
  • Director of Institute
  • Director of National Reference Center
  • Group Leader
  • Head of Facility
  • Head of Operations
  • Head of Structure
  • Honorary President of the Departement
  • Labex Coordinator
Content 2
  • member
  • team
  • department
  • center
  • program_project
  • nrc
  • whocc
  • project
  • software
  • tool
  • patent
  • Administrative Staff
  • Assistant Professor
  • Associate Professor
  • Clinical Research Assistant
  • Clinical Research Nurse
  • Clinician Researcher
  • Department Manager
  • Dual-education Student
  • Full Professor
  • Honorary Professor
  • Lab assistant
  • Master Student
  • Non-permanent Researcher
  • Nursing Staff
  • Permanent Researcher
  • Pharmacist
  • PhD Student
  • Physician
  • Post-doc
  • Prize
  • Project Manager
  • Research Associate
  • Research Engineer
  • Retired scientist
  • Technician
  • Undergraduate Student
  • Veterinary
  • Visiting Scientist
  • Deputy Director of Center
  • Deputy Director of Department
  • Deputy Director of National Reference Center
  • Deputy Head of Facility
  • Director of Center
  • Director of Department
  • Director of Institute
  • Director of National Reference Center
  • Group Leader
  • Head of Facility
  • Head of Operations
  • Head of Structure
  • Honorary President of the Departement
  • Labex Coordinator
Search
Go back
Scroll to top
Share
© NIAID - CC by 2.0
Based on 'Human Natural Killer Cell' and 'Human B lymphocyte' from NIAID
Starting Date
01
Mar 2012
Ending Date
01
Jan 2019
Status
Ongoing
Members
6
Structures
1

About

CyaA-based therapeutic cancer vaccines

Based on our discovery that a bacterial protein, the adenylate cyclase (CyaA), binds to dendritic cells (DCs), we have developed a highly efficient vector capable of targeting a wide range of antigens to antigen presenting cells (APC), leading to strong immune responses. A large panel of recombinant CyaAs carrying different heterologous viral and/or tumoral T-cell epitopes were shown to stimulate strong and specific Th1 and CTL responses in animals, and to induce protective immunity against viral and tumoral challenges, as well as therapeutic efficacy against transplanted tumors. We recently demonstrated that CyaA possesses the intrinsic ability not only to target DCs but also to activate them through the TLR4/TIR domain containing adapter-inducing IFN-ß (TRIF) pathway, leading to the induction of strong immune responses (Dadaglio et al, J. Immunol, 2014). We used this new vector to develop two therapeutic vaccine candidates against cervical cancer (ProCervix) and melanoma (Theravac) which have entered in clinical trials. ProCervix, based on the CyaA vector, is a bivalent HPV therapeutic vaccine candidate currently evaluated in a large Phase I clinical trial for women who are infected with HPV 16 and/or HPV 18, before appearance of high grade cervical lesions. Clinical phase I trial results in 47 patients indicate good safety and local tolerance at the highest dose evaluated. Antigen-specific T cell responses have been detected in a majority of vaccinated women. Moreover, viral clearance is markedly more frequent in patients treated with ProCervix than in the placebo group. In addition, only the group of patients vaccinated with ProCervix controlled HPV recurrence (http://www.genticel.com/). image068.png

The MAG-Tn3 vaccine

A hallmark of cancer cells is a change in glycosylation processes leading to the abnormal expression of carbohydrate chains, such as antigens of the T family (Tn, sialyl-Tn and T) on most carcinomas (breast, colon, prostate and ovary). We have developed an efficient approach based on a fully synthetic glycopeptide structure, for the induction of antibodies against the Tn glycosidic antigen expressed by tumor cells. image070.png This molecule, namely MAG-Tn3, is a glycopeptidic dendrimer including the Tn antigen and a pan-DR T cell epitope from tetanus toxin and represents the first example of a fully synthetic glycosidic vaccine with immunotherapeutic potential against cancer. We are currently organizing a Phase I clinical trial of the MAG-Tn3, which is planned to start in 2015.